Eli Lilly secures FDA approval for Olumiant in pediatric alopecia areata, marking a key label expansion following successful Phase 3 clinical trial results.
FDA approval of Olumiant for pediatric alopecia areata expands Lilly's label and addresses an unmet medical need, supporting revenue growth.
The FDA has granted approval for Eli Lilly's Olumiant to treat pediatric patients suffering from severe alopecia areata. This expansion of the drug's label follows positive results from the Phase 3 BRAVE-AA-PEDS study, which demonstrated significant scalp hair regrowth and improvements in eyebrow and eyelash coverage.
The approval allows Eli Lilly to market Olumiant for a younger patient demographic, addressing a significant unmet medical need and providing a new revenue stream in the dermatology segment.